Comparing Carboplatin Alone vs. Carboplatin with Chlorambucil in Ovarian Cancer
Author Information
Author(s): E.M. Rankin, L. Mill, S.B. Kaye, R. Atkinson, L. Cassidy, J. Cordiner, D. Cruickshank, J. Davis, I.D. Duncan, W. Fullerton, T. Habeshaw, J. Kennedy, R. Kennedy, H. Kitchener, A. MacLean, J. Paul, N. Reed, T. Sarker, M. Soukop, G.H. Swapp, R.P. Symonds
Primary Institution: Beatson Oncology Centre, Western Infirmary, Glasgow
Hypothesis
Is there a clinically significant difference in treatment results between the use of carboplatin as a single agent at full dose and its use in combination with chlorambucil?
Conclusion
There is no major clinical advantage to adding chlorambucil to carboplatin for treating advanced ovarian cancer.
Supporting Evidence
- The median progression-free survival was similar for both treatment arms.
- 52% of patients received dose escalations based on blood counts.
- Failure to achieve significant leucopenia was associated with worse progression-free survival.
Takeaway
Doctors wanted to see if using two medicines together would work better than just one for women with advanced ovarian cancer, but they found out that using just one medicine was just as good.
Methodology
Patients were randomized to receive either carboplatin alone or carboplatin with chlorambucil, and their progression-free survival and overall survival were compared.
Limitations
The study was closed early, and the sample size was smaller than initially planned.
Participant Demographics
Patients were previously untreated women with FIGO stage III or IV epithelial ovarian cancer.
Statistical Information
P-Value
0.830
Confidence Interval
0.67-1.39
Statistical Significance
p=0.830
Want to read the original?
Access the complete publication on the publisher's website